Evaluating the Role of Apple Cider Vinegar in Managing Semaglutide-Induced Gastrointestinal Disturbances: A Systematic Review

Year : 2025 | Volume : 15 | Issue : 01 | Page : 25 31
    By

    Mohammad Nadeem Khan,

  1. Senior Clinical Research Associate, Department of Clinical Pharmacology, Sri Aurobindo Medical College & PG Institute, Sanwer Road, Indore, Madhya Pradesh, India

Abstract

Background: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is highly effective in treating type 2 diabetes and obesity. However, its use is often associated with gastrointestinal side effects, including nausea, vomiting, and diarrhea, which may impact patient compliance. Objective: This systematic review aims to evaluate the evidence regarding the management of semaglutide-induced GI symptoms and assess the potential role of apple cider vinegar (ACV) as a complementary treatment. Methods: A comprehensive search of databases, including PubMed, Cochrane Library, and Scopus, was conducted for studies published in the last five years. The inclusion criteria consisted of randomized controlled trials (RCTs), observational studies, and case reports that examined gastrointestinal symptoms caused by semaglutide and the application of ACV. Results: The initial search yielded 120 articles, with 15 meeting the inclusion criteria. Most studies reported common GI side effects associated with semaglutide, particularly nausea and diarrhea. While direct evidence supporting ACV’s efficacy in managing these symptoms is limited, anecdotal reports and preliminary studies suggest that ACV may help improve digestion and reduce nausea. Conclusion: Semaglutide is a valuable treatment option for type 2 diabetes and obesity, but its GI side effects pose challenges in clinical practice. This review highlights the potential of apple cider vinegar as a complementary approach to alleviating these disturbances. Further clinical trials are necessary to validate the safety and efficacy of ACV in managing semaglutide-induced gastrointestinal symptoms.

Keywords: Semaglutide, GLP-1receptoragonist, gastrointestinal disturbances, apple cider vinegar, nausea, diarrhea, type 2 diabetes, obesity, complementary therapy

[This article belongs to Research and Reviews: A Journal of Medicine ]

How to cite this article:
Mohammad Nadeem Khan. Evaluating the Role of Apple Cider Vinegar in Managing Semaglutide-Induced Gastrointestinal Disturbances: A Systematic Review. Research and Reviews: A Journal of Medicine. 2025; 15(01):25-31.
How to cite this URL:
Mohammad Nadeem Khan. Evaluating the Role of Apple Cider Vinegar in Managing Semaglutide-Induced Gastrointestinal Disturbances: A Systematic Review. Research and Reviews: A Journal of Medicine. 2025; 15(01):25-31. Available from: https://journals.stmjournals.com/rrjom/article=2025/view=195791


References

  1. Smith A, Johnson B. GLP-1 receptor agonists in the management of T2DM. Diabetes Care. 2020;43(4):612–620. doi:10.2337/dc20-0602.
  2. Miller C, Roberts L. Semaglutide for obesity: A new weight-loss option. Obes Rev. 2021;22(3):e13275. doi:10.1111/obr.13275.
  3. Brown P, Taylor R, Anderson M. Managing type 2 diabetes with semaglutide: A clinical overview. J Clin Endocrinol. 2022;107(9):2506–2515. doi:10.1210/clinem/dgac456.
  4. Taylor S. Gastrointestinal effects of GLP-1 receptor agonists. Am J Gastroenterol. 2019;114(5):734–742. doi:10.14309/ajg.0000000000000260.
  5. Anderson G, Mitchell A, Stone J. The role of delayed gastric emptying in GLP-1 therapy. J Diabetes Res. 2021;2021:8912396. doi:10.1155/2021/8912396.
  6. Davis R, Lee J. Addressing side effects in GLP-1 receptor agonist therapy. Int J Diabetes Complications. 2022;10(2):87–94. doi:10.1016/j.ijdc.2022.010301.
  7. Carter D, Mason T, Hall W. Management strategies for semaglutide-induced gastrointestinal side effects. Clin Ther. 2023;45(3):312–321. doi:10.1016/j.clinthera.2023.02.003.
  8. Green H, O’Connor P, Singh R. Apple cider vinegar: Traditional uses and modern applications. Phytomed. 2021;86:153224. doi:10.1016/j.phymed.2021.153224.
  9. Kumar P. The prebiotic potential of apple cider vinegar. J Gastroenterol Nutr. 2022;74(1):15–22. doi:10.1097/MPG.0000000000003408.
  10. Martinez L, Perez M, Thompson J. Apple cider vinegar: A review of gastrointestinal health benefits. J Nutr Health. 2023;57(2):88–95. doi:10.1007/s13501-022-00710-3.
  11. Wallace T, Brown M. Can apple cider vinegar alleviate nausea? A preliminary study. Complement Ther Med. 2022;65:102789. doi:10.1016/j.ctim.2022.102789.
  12. Fleming J, Wright G, Davis H. Apple cider vinegar and gut health: An overview. Nutr J. 2020;19(1):13–22. doi:10.1186/s12937-020-00588-2.
  13. Nguyen P, Tran Q, Yang S. The effect of ACV on digestive symptoms. J Altern Med. 2019;24(4):155–162. doi:10.1089/jam.2019.0034.
  14. Roberts L, Patel A, Zheng C. Future directions in GLP-1 receptor agonist therapy. Lancet Diabetes Endocrinol. 2020;8(1):75–83. doi:10.1016/S2213-8587(19)30212-3.
  15. Griffin S. Managing gastrointestinal symptoms in diabetes patients. Diabetes Ther. 2022;13(4):801–813. doi:10.1007/s13300-022-01246-x.
  16. Sharma N, Iyer K, Patel P. The role of the gut microbiome in gastrointestinal disorders. Gut Microbes. 2021;12(1):183–195. doi:10.1080/19490976.2021.1823190.
  17. Miller T, Smith R, Johnson K. Holistic approaches to drug-induced GI disturbances. J Integr Health. 2023;11(3):245–256. doi:10.1016/j.jih.2023.01.005.
  18. Zhang Y, Chen J, Li X. Emerging trends in GLP-1 receptor agonist therapies. Endocrinol Metab. 2021;36(2):165–174. doi:10.1007/s00204-021-03022-8.
Regular Issue Subscription Review Article
Volume 15
Issue 01
Received 08/11/2024
Accepted 14/11/2024
Published 29/01/2025
Publication Time 82 Days
305

Login


My IP

PlumX Metrics